Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
Sulindac for Patients With AML
- Status
- WITHDRAWN
- Phase
- PHASE2
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- NA
Brentuximab Vedotin + Re-induction Chemotherapy for AML
- Status
- COMPLETED
- Phase
- PHASE1
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Alisertib for Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- NA
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
- Status
- COMPLETED
- Phase
- PHASE3
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1